Scott Cruickshank
Impact in
Papers in
- Oncology 26
- Colorectal Cancer Treatments and Studies 8
- Cancer Treatment and Pharmacology 7
- HER2/EGFR in Cancer Research 5
-
- Lung Cancer Treatments and Mutations 9
- Advanced Breast Cancer Therapies 5
- Co-authors
- Christina A. Meyers (1 shared paper)Aman U. Buzdar (1 shared paper)Renato Lenzi (1 shared paper)Richard L. Theriault (1 shared paper)Jeffrey S. Wefel (1 shared paper)Denise A. Yardley (5 shared papers)Jane B. Trepel (3 shared papers)Steven G. DuBois (7 shared papers)
- Journals
- Journal of Clinical Oncology (16 papers)Annals of Oncology (6 papers)Cancer Research (4 papers)Blood (4 papers)Cancer (2 papers)
- Partner nations
- United StatesCanadaDenmark
In The Last Decade
Scott Cruickshank
56 papers receiving 2.6k citations
Scott Cruickshank's Hit Papers
Peers
Comparison fields: 5 of 95
- Genetics 582
- Oncology 1.2k
- Pulmonary and Respiratory Medicine 1.0k
- Hematology 283
- Cancer Research 368
Countries citing papers authored by Scott Cruickshank
This map shows the geographic impact of Scott Cruickshank's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott Cruickshank with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott Cruickshank more than expected).
Fields of papers citing papers by Scott Cruickshank
This network shows the impact of papers produced by Scott Cruickshank. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott Cruickshank. The network helps show where Scott Cruickshank may publish in the future.
Co-authors
The 25 scholars most cited alongside Scott Cruickshank, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 56 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study Hit paper breakdown → | 2018 | 378 |
| 2 | 2013 | 317 | |
| 3 | A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study Hit paper breakdown → | 2015 | 313 |
| 4 | 2004 | 243 | |
| 5 | 2015 | 145 | |
| 6 | 1994 | 129 | |
| 7 | 2019 | 114 | |
| 8 | 2018 | 100 | |
| 9 | 2018 | 89 | |
| 10 | 2007 | 79 | |
| 11 | 2014 | 76 | |
| 12 | 2017 | 62 | |
| 13 | 2016 | 58 | |
| 14 | 2009 | 46 | |
| 15 | 2016 | 40 | |
| 16 | 2000 | 36 | |
| 17 | 2018 | 31 | |
| 18 | 2005 | 31 | |
| 19 | 2013 | 26 | |
| 20 | 2002 | 24 |
About Scott Cruickshank
Scott Cruickshank is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Hematology and Genetics, having authored 56 papers that have together received 2.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (9 papers), Protein Degradation and Inhibitors (8 papers), Colorectal Cancer Treatments and Studies (8 papers), Cancer Treatment and Pharmacology (7 papers), Histone Deacetylase Inhibitors Research (7 papers), Multiple Myeloma Research and Treatments (6 papers), HER2/EGFR in Cancer Research (5 papers) and Advanced Breast Cancer Therapies (5 papers). The work is most often cited by research in Genetics (582 citations), Oncology (1.2k citations), Pulmonary and Respiratory Medicine (1.0k citations), Hematology (283 citations) and Cancer Research (368 citations). Scott Cruickshank has collaborated with scholars based in United States, Canada and Denmark. Frequent co-authors include Christina A. Meyers, Aman U. Buzdar, Renato Lenzi, Richard L. Theriault, Jeffrey S. Wefel, Denise A. Yardley, Jane B. Trepel, Steven G. DuBois, Pamela Klein and Ramamoorthy Nagasubramanian. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Blood and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.